Salicylic Acid + Lactic Acid interactions
Checked as Salicylic acid + Lactic acid in this data source.
Full monograph for Salicylic Acid + Lactic AcidCheck it against another medicine
Medicines
275 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acetazolamidevia Salicylic acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Deferasiroxvia Salicylic acid | Major | Synergy | Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. | 2 sources — open the full entry |
| Dorzolamide + Timololvia Salicylic acid | Major | Antagonism · Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate…2 documented mechanisms | 22 sources — open the full entry |
| Ketorolac Tromethaminevia Salicylic acid | Major | Synergy | The use of ketorolac in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious adverse effects such as renal… | 1 sources — open the full entry |
| Leflunomidevia Salicylic acid | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity… | 3 sources — open the full entry |
| Methotrexatevia Lactic acid, Salicylic acid | Major | Distribution · Excretion | Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites.2 documented mechanisms | 20 sources — open the full entry |
| Monobasic Sodium Phosphate + Dibasic Sodium Phosphatevia Salicylic acid | Major | Others | The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing… | 3 sources — open the full entry |
| Ramucirumabvia Salicylic acid | Major | Synergy | Theoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal… | 1 sources — open the full entry |
| Activated Charcoalvia Salicylic acid | Moderate | Absorption | Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. | 25 sources — open the full entry |
| Acyclovir + Hydrocortisonevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Alendronic acidvia Salicylic acid | Moderate | Synergy | Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates… | 11 sources — open the full entry |
| Alendronic Acid + Vitamin D3via Salicylic acid | Moderate | Synergy | Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates… | 11 sources — open the full entry |
| Allium cepa + Heparin + Allantoinvia Salicylic acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Alteplasevia Salicylic acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Salicylic acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 8 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Salicylic acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism…2 documented mechanisms | 8 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicatevia Salicylic acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
| Amikacinvia Salicylic acid | Moderate | Synergy | The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in… | 6 sources — open the full entry |
| Amlodipine Besilatevia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to… | 9 sources — open the full entry |
| Amlodipine Besilate + Atenololvia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 15 sources — open the full entry |
| Amlodipine Besilate + Atorvastatinvia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to… | 9 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloridevia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 22 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomilvia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 13 sources — open the full entry |
| Amlodipine Besilate + Telmisartanvia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 13 sources — open the full entry |
| Amlodipine Besilate + Valsartanvia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 13 sources — open the full entry |
| Apixabanvia Salicylic acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Aspirinvia Lactic acid, Salicylic acid | Moderate | Excretion · Synergy | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other…2 documented mechanisms | 7 sources — open the full entry |
| Aspirin + Dipyridamolevia Lactic acid, Salicylic acid | Moderate | Excretion · Synergy | Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other…2 documented mechanisms | 7 sources — open the full entry |
| Azilsartan Medoxomilvia Salicylic acid | Moderate | Antagonism | Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is… | 4 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidonevia Salicylic acid | Moderate | Antagonism | Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is… | 4 sources — open the full entry |
| Baricitinibvia Salicylic acid | Moderate | Synergy | Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of… | 15 sources — open the full entry |
| Betamethasonevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Calcipotriolvia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Clotrimazolevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicinvia Salicylic acid | Moderate | Excretion · Metabolism · Synergy | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may…2 documented mechanisms | 11 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic)via Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocainevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Dipropionatevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acidvia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Sodium Phosphatevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betamethasone Valeratevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Betrixabanvia Salicylic acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| Biphasic Insulin Aspartvia Salicylic acid | Moderate | Synergy | The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines… | 76 sources — open the full entry |
| Bismuth Subsalicylatevia Salicylic acid | Moderate | Synergy | Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding… | 2 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilatevia Salicylic acid | Moderate | Antagonism | Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to…2 documented mechanisms | 15 sources — open the full entry |
| Bivalirudinvia Salicylic acid | Moderate | Synergy | Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. | 8 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTabletvia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Budesonide + Formoterol Fumaratevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumaratevia Salicylic acid | Moderate | Excretion · Metabolism | Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may… | 5 sources — open the full entry |
| Calcium acetate + Magnesium carbonatevia Salicylic acid | Moderate | Excretion | Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism… | 8 sources — open the full entry |
Conditions
Conditions in which Salicylic Acid + Lactic Acid needs care, as documented in this source.
Acidosis, Lactic
MajorLactate metabolism results in production of bicarbonate. Bicarbonate generation is impaired in patients with compromised liver function and/or disorders that decrease tissue perfusion and increase anoxia. Therapy with sodium lactate should not be used in conditions in which lactate levels are increased (e.g., shock, congestive heart failure, respiratory alkalosis) or in which utilization of lactate is diminished (e.g., anoxia, beriberi). Sodium lactate is not for use in the treatment of lactic acidosis.
1 source
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical (2001):
Water-Electrolyte Imbalance
MajorAlkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.
2 sources
- "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra-Zeneca Pharmaceuticals (2001):
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical (2001):
Acid-Base Imbalance
ModerateAlkalinizing agents act as proton acceptors and/or dissociate to provide bicarbonate ions. Elimination of bicarbonate is decreased in patients with renal impairment and can result in metabolic alkalosis. Symptoms of metabolic alkalosis include hyperirritability or tetany, arrhythmia, and/or seizures (altered pH = altered calcium), or lactic acidosis due to impaired oxygen release. Therapy with alkalinizing agents should be administered with extreme caution in patients with compromised renal function. Clinical monitoring of renal function, acid/base balance and electrolytes is recommended.
3 sources
- "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company
- "Product Information. Tham (tromethamine)." Abbott Pharmaceutical (2001):
- "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical (2001):
Therapeutic duplication
Drug classes that overlap with Salicylic Acid + Lactic Acid, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Laniroif
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Consensi
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Synalgos-dc
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Esomeprazole/naproxen
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Acetaminophen/caffeine/magnesium salicylate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Trilisate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Phosphasal
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Orphengesic forte
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Acetaminophen/magnesium salicylate/pamabrom
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/citric acid/sodium bicarbonate
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Soma compound with codeine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Stanback
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/methocarbamol
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/carisoprodol
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Micrainin
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/butalbital/caffeine/codeine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Acetaminophen/ibuprofen
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/chlorpheniramine/dextromethorphan/phenylpropanolamine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Percodan
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Doans pm
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/omeprazole
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/dipyridamole
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Migraine relief
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Prosed ds
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/chlorpheniramine/phenylephrine
nonsteroidal anti-inflammatories
The recommended maximum number of medicines in the 'nonsteroidal anti-inflammatories' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'nonsteroidal anti-inflammatories' category.
Example product in the source data (US market): Aspirin/hydrocodone
systemic alkalinizing agents
The recommended maximum number of medicines in the 'systemic alkalinizing agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'systemic alkalinizing agents' category.
Example product in the source data (US market): Aspirin/citric acid/sodium bicarbonate